摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(6-氯-3-吡啶)-丙烯酸乙酯 | 159153-39-6

中文名称
3-(6-氯-3-吡啶)-丙烯酸乙酯
中文别名
——
英文名称
ethyl 3-(6-chloropyridin-3-yl)acrylate
英文别名
ethyl (E)-3-(6-chloropyridin-3-yl)acrylate;(E)-ethyl 3-(6-chloropyridin-3-yl)acrylate;Ethyl β-(2-chloropyridin-5-yl)acrylate;ethyl (2E)-3-(6-chloro-3-pyridyl)acrylate;3-(6-Chloro-pyridin-3-yl)-acrylic acid ethyl ester;ethyl (E)-3-(6-chloropyridin-3-yl)prop-2-enoate
3-(6-氯-3-吡啶)-丙烯酸乙酯化学式
CAS
159153-39-6
化学式
C10H10ClNO2
mdl
——
分子量
211.648
InChiKey
FHRIBCCVJCCJCZ-GQCTYLIASA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    81 °C
  • 沸点:
    325.4±27.0 °C(Predicted)
  • 密度:
    1.229±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    14
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    39.2
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 危险等级:
    IRRITANT
  • 危险品标志:
    Xi
  • 海关编码:
    2933399090
  • 危险类别:
    IRRITANT
  • WGK Germany:
    3
  • 危险标志:
    GHS07
  • 危险性描述:
    H315,H319,H335
  • 危险性防范说明:
    P305 + P351 + P338

SDS

SDS:1e22d768aa8f74e623c80af898a9a56f
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Synthesis and Antifungal Activities of R-102557 and Related Dioxane-Triazole Derivatives.
    摘要:
    具有二噁烷环的新型三唑化合物被合成。在酸性条件下,二醇前体10与各种芳香醛11-13缩合,得到了一系列二噁烷-三唑化合物14-16。这些化合物14-16的抗真菌活性通过在小鼠感染模型中对白色念珠菌和曲霉菌的评估进行了体内评价。含有单个或两个双键且侧链上带有吸电子基团的芳环衍生物表现出较高的活性。在这些衍生物中,R-102557(16R:Ar=4-(2,2,3,3-四氟丙氧基)苯基)对白色念珠菌、曲霉菌和隐球菌属表现出极佳的体内活性。在大鼠的初步毒性研究中也显示出高度耐受性。
    DOI:
    10.1248/cpb.48.694
  • 作为产物:
    描述:
    6-氯烟酸甲酯 在 lithium aluminium tetrahydride 、 potassium tert-butylatepyridinium chlorochromate 作用下, 以 四氢呋喃二氯甲烷 为溶剂, 反应 7.0h, 生成 3-(6-氯-3-吡啶)-丙烯酸乙酯
    参考文献:
    名称:
    Design, Synthesis, and Characterization of α-Ketoheterocycles That Additionally Target the Cytosolic Port Cys269 of Fatty Acid Amide Hydrolase
    摘要:
    A series of alpha-ketooxazoles incorporating electrophiles at the C5 position of the pyridyl ring of 2 (OL-135) and related compounds were prepared and examined as inhibitors of fatty acid amide hydrolase (FAAH) that additionally target the cytosolic port Cys269. From this series, a subset of the candidate inhibitors exhibited time-dependent FAAH inhibition and noncompetitive irreversible inactivation of the enzyme, consistent with the targeted Cys269 covalent alkylation or addition, and maintained or enhanced the intrinsic selectivity for FAAH versus other serine hydrolases. A preliminary in vivo assessment demonstrates that these inhibitors raise endogenous brain levels of anandamide and other FAAH substrates upon intraperitoneal (i.p.) administration to mice, with peak levels achieved within 1.5-3 h, and that the elevations of the signaling lipids were maintained >6 h, indicating that the inhibitors effectively reach and remain active in the brain, inhibiting FAAH for a sustained period.
    DOI:
    10.1021/jm401820q
点击查看最新优质反应信息

文献信息

  • Dimethyl Sulfoxide Mediated Elimination Reactions in 3-Aryl 2,3-Dihalopropanoates:  Scope and Mechanistic Insights
    作者:Wei Li、Jianchang Li、Melissa Lin、Sumrit Wacharasindhu、Keiko Tabei、Tarek S. Mansour
    DOI:10.1021/jo070217c
    日期:2007.8.1
    Dimethyl sulfoxide (DMSO) efficiently causes the reductive elimination of 3-aryl 2,3-dibromopropanoates to cinnamates with good yield. With 3-phenyl 2,3-dihalopropanoates, debromination is the major pathway providing 3-phenylacrylate derivatives in high yields, whereas dehydrobromination is a competing pathway with thiophene derivatives. 1H NMR, 81Br NMR, and MS techniques indicated the formation of
    二甲基亚砜(DMSO)有效地导致3-芳基2,3-二溴丙酸酯的还原消除为肉桂酸酯,收率良好。对于3-苯基2,3-二卤代丙酸酯,脱溴是提供高收率的3-苯基丙烯酸酯衍生物的主要途径,而脱氢溴化是与噻吩衍生物竞争的途径。1 H NMR,81 Br NMR和MS技术表明,在该转化过程中形成了副产物溴化DMSO,MeBr和HBr,没有证据表明形成了Br 2。DMSO作为亲核试剂和溴清除剂的双重作用解释了该反应中形成的产物。
  • Ruthenium-Catalyzed Heck-Type Olefination and Suzuki Coupling Reactions:  Studies on the Nature of Catalytic Species
    作者:Youngim Na、Soyoung Park、Soo Bong Han、Hoon Han、Sangwon Ko、Sukbok Chang
    DOI:10.1021/ja038742q
    日期:2004.1.1
    When starting with a ruthenium complex [RuCl(2)(p-cymene)](2) as a homogeneous catalyst precursor, induction periods were observed and ruthenium colloids of zero oxidation state were generated under catalytic conditions. Isolated ruthenium colloids carried out the olefination, implying that active catalytic species are ruthenium nanoclusters. To support this hypothesis, ruthenium nanoparticles stabilized
    已经开发了钌催化的 Heck 烯化和 Suzuki 交叉偶联反应。当以钌配合物 [RuCl(2)(p-cymene)](2) 作为均质催化剂前体开始时,观察到诱导期,并在催化条件下生成零氧化态的钌胶体。分离出的钌胶体进行烯化,表明活性催化物质是钌纳米团簇。为了支持这一假设,通过氢化物还原程序独立制备了用十二胺稳定的钌纳米颗粒,并随后检查了它们的催化活性。在相同条件下,钌纳米颗粒有效地催化了碘苯与丙烯酸乙酯的烯烃化,其也可用于下一次运行。在中毒实验中,在汞的存在下,烯烃化的转化被完全抑制,从而支持我们对催化物种性质的假设。在反应结束时从滤液中没有检测到残留的钌。在此假设的基础上,首次开发了氧化铝负载钌的多相催化剂体系,用于Heck烯化和Suzuki交叉偶联反应。结果表明,与均相预催化剂的结果相比,即使在较温和的反应条件下,无外部配体催化剂的底物范围和选择性也显着提高。还观察到固定的钌催化剂被
  • [EN] HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS D'HISTONE DÉSACÉTYLASE, ET COMPOSITIONS ET PROCÉDÉS POUR LES UTILISER
    申请人:CHDI FOUNDATION INC
    公开号:WO2012103008A1
    公开(公告)日:2012-08-02
    Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.
    提供了某些Formula I的组蛋白去乙酰化酶(HDAC)抑制剂,以及它们的组合物和使用方法。
  • [EN] HYDROXYAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF HISTONE DEACETYLASE (HDAC)<br/>[FR] COMPOSÉS D'HYDROXYAMIDE PRÉSENTANT UNE ACTIVITÉ EN TANT QU'INHIBITEURS D'HISTONE DÉSACÉTYLASE (HDAC)
    申请人:ASTELLAS PHARMA INC
    公开号:WO2006016680A1
    公开(公告)日:2006-02-16
    A compound having the following formula (I): wherein R1 is hydrogen, lower alkyl, lower alkenyl, lower or higher alkynyl, cyclo(lower)alkyl, cyclo(higher)alkyl, cyclo(lower)alkyl(lower)alkyl, cyclo(higher)alkyl(lower)alkyl, cyclo(lower)alkenyl(lower)alkyl, aryl-fused cyclo(lower)alkyl, lower alkoxy, acyl, aryl, ar(lower)alkoxy, ar(lower)alkyl, heteroar(lower)alkyl, amino, heteroaryl, heterocyclyl or heterocyclyl(lower)alkyl, which may be substituted with one or more suitable substituent(s),R2 is hydrogen or lower alkyl, X is arylene, heteroarylene, cycloalkylene, heterocycloalkylene or aryl-fused cycloalkylene, Y is arylene or heteroarylene, which may be substituted with one or more suitable substituent(s), Z is lower alkenylene, which may be substituted with lower alkyl or halogen, or a salt thereof. The compound is useful as a histone deacetylase inhibitor.
    一种具有以下化学式(I)的化合物:其中R1是氢、低烷基、低烯基、低或高炔基、环(低)烷基、环(高)烷基、环(低)烷基(低)烷基、环(高)烷基(低)烷基、环(低)烯基(低)烷基、芳基-融合环(低)烷基、低烷氧基、酰基、芳基、芳基(低)氧基、芳基(低)烷基、杂环芳基(低)烷基、氨基、杂环芳基、杂环烷基或杂环烷基(低)烷基,可以用一个或多个适当的取代基替换;R2是氢或低烷基,X是芳基、杂环芳基、环烷基、杂环环烷基或芳基-融合环烷基,Y是芳基或杂环芳基,可以用一个或多个适当的取代基替换;Z是低烯基,可以用低烷基或卤素取代,或其盐。该化合物可用作组蛋白去乙酰化酶抑制剂。
  • Therapeutic phenoxyalkylheterocycles
    申请人:Sanofi, S.A.
    公开号:US05618821A1
    公开(公告)日:1997-04-08
    Compounds of the formula ##STR1## wherein Q is chosen from the group consisting of pyridyl, pyrazyl, pyrimidyl, quinolyl, indolyl and 7-azaindolyl or any of these substituted with one or two substituents; Y is an alkylene bridge of 3-9 carbon atoms; R.sub.1 and R.sub.2 are each independently chosen from hydrogen, halo, alkyl, alkenyl, amino, alkylthio, hydroxy, hydroxyalkyl, alkoxyalkyl, alkylthioalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, alkoxy, nitro, carboxy, alkoxycarbonyl, dialkylaminoalkyl, alkylaminoalkyl, aminoalkyl, difluoromethyl, trifluoromethyl or cyano; R.sub.3 is alkoxycarbonyl, alkyltetrazolyl, substituted or unsubstituted phenyl or heterocyclyl, the N-oxide thereof, or a pharmaceutically acceptable acid addition salt thereof is an effective antipicornaviral agent.
    式##STR1##中的化合物,其中Q选择自吡啶基、吡唑基、嘧啶基、喹啉基、吲哚基和7-吡啶基中的一种或这些基中的一种或两种取代基; Y是3-9个碳原子的烷基桥; R.sub.1和R.sub.2分别独立地选择自氢、卤素、烷基、烯基、氨基、烷硫基、羟基、羟基烷基、烷氧基烷基、烷硫基烷基、烷基磺基烷基、烷氧基、硝基、羧基、烷氧羰基、二烷基氨基烷基、烷基氨基烷基、氨基烷基、二氟甲基、三氟甲基或氰基; R.sub.3是烷氧羰基、烷基四唑基、取代或未取代的苯基或杂环基,其N-氧化物,或其药用可接受的酸盐是一种有效的抗小肠病毒药剂。
查看更多